In her presentation at the 44th Annual J.P. Morgan Healthcare Conference, CEO Katherine Stueland highlighted that GeneDx achieved over 30% growth in both testing volume and revenue in 2025. The company delivered $427 million in full-year revenue while maintaining gross margins above 70% and generating positive net income. Management attributed this performance to expanded pediatric genetic screening programs at three leading children’s hospitals and the launch of two new specialty panels, which together accounted for a 15% uplift in average order value. GeneDx ended the year with a backlog of 12,000 orders, representing a 25% increase versus the prior year, and reduced turnaround time for exome sequencing to an average of nine days.

Preliminary fourth-quarter results met guidance but did not significantly exceed consensus estimates, prompting a modest share retracement. Revenue for the quarter was reported at $120 million, up 28% year-over-year, with gross margins steady at 71%. CFO Kevin Feeley noted that operational investments in automated sample processing and hiring of 40 additional laboratory technicians will drive capacity for projected volume growth of 33% to 35% in 2026. The company reiterated full-year revenue guidance of $570 million to $590 million, reflecting the planned contribution from two new partnerships with regional health networks and an expanded rare-disease data analytics platform expected to launch in Q2.